Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ARWR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Pri… NCT07221344 · Alzheimer Disease, Tauopathies ARO-MAPT-SC, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | 160 | Jun 2027 | Registry ↗ |
| Oct 30, 2026 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus NCT06700538 · Obesity ARO-INHBE, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Active, not recruiting was recruiting | 190 | Oct 15, 2027 | Registry ↗ |
| Oct 26, 2026 | Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia NCT07473843 · Homozygous Familial Hypercholesterolemia Zodasiran | ARWR Arrowhead Pharmaceuticals | Phase 3 | Recruiting | 10 | Jul 2028 | Registry ↗ |
| Oct 13, 2026 | Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia NCT07223658 · Hyperlipidemia; Mixed ARO-DIMERPA, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | 78 | Jul 2027 | Registry ↗ |
| Oct 9, 2026 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia NCT06347016 · Severe Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Completed | 311 | Jun 17, 2026 | Registry ↗ |
| Oct 8, 2026 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia NCT06347003 · Severe Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Completed | 446 | Jun 12, 2026 | Registry ↗ |
| Oct 6, 2026 | A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Assoc… NCT07859813 · Metabolic Dysfunction-Associated Steatohepatitis ARO-INHBE, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Not yet recruiting | 252 | Oct 2029 | Registry ↗ |
| Oct 1, 2026 | Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma NCT07241546 · Asthma ARO-RAGE, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Recruiting | 36 | Dec 2027 | Registry ↗ |
| Oct 1, 2026 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia NCT06822790 · Hypertriglyceridemia Plozasiran Injection | ARWR Arrowhead Pharmaceuticals | Phase 3 | Active, not recruiting | 710 | Jul 2028 | Registry ↗ |
| Sep 25, 2026 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia NCT06347133 · Hypertriglyceridemia Plozasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Completed | 1,456 | Jun 1, 2026 | Registry ↗ |
| Sep 21, 2026 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis NCT06880770 · Severe Hypertriglyceridemia Plozasiran, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Recruiting | 288 | Mar 2029 | Registry ↗ |
| Sep 15, 2026 | A First-In-Human Study of ARO-033 in Adult Participants NCT07662096 · Age-related Macular Degeneration ARO-033, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Recruiting | 84 | Jul 1, 2028 | Registry ↗ |
| Sep 14, 2026 | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease NCT05292950 · Asthma, Chronic Obstructive Pulmonary Disease ARO-MUC5AC, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Terminated | 78 | Nov 12, 2024 | Registry ↗ |
| Aug 12, 2026 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholest… NCT07037771 · Homozygous Familial Hypercholesterolemia zodasiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Active, not recruiting | 70 | Aug 20, 2027 | Registry ↗ |
| Aug 5, 2026 | Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulm… NCT05537025 · Idiopathic Pulmonary Fibrosis ARO-MMP7 Inhalation Solution, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Completed | 105 | Sep 5, 2025 | Registry ↗ |
| Jul 8, 2026 | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus NCT06937203 · Obesity, Diabetes Mellitus, Type 2 ARO-ALK7, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Recruiting | 150 | Feb 2027 | Registry ↗ |
| Jun 29, 2026 | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 NCT06672445 · Spinocerebellar Ataxia Type 2 ARO-ATXN2 Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Active, not recruiting | 39 | Dec 2026 | Registry ↗ |
| Jun 12, 2026 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) NCT05217667 · Homozygous Familial Hypercholesterolemia ARO-ANG 3 Injection | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 18 | May 2, 2023 | Registry ↗ |
| Jun 5, 2026 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) NCT05089084 · Familial Chylomicronemia Plozasiran, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 3 | Completed | 75 | Apr 29, 2024 | Registry ↗ |
| May 22, 2026 | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease NCT05083364 · C3 Glomerulopathy, IgA Nephropathy ARO-C3, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Completed | 62 | Sep 10, 2025 | Registry ↗ |
| May 20, 2026 | Study of ARO-CFB in Adult Healthy Volunteers NCT06209177 · IgA Nephropathy ARO-CFB, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 49 | Mar 31, 2025 | Registry ↗ |
| May 12, 2026 | Study of ARO-APOC3 in Adults With Dyslipidemia NCT05413135 · Dyslipidemias ARO-APOC3 | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 418 | Sep 22, 2025 | Registry ↗ |
| Apr 14, 2026 | Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia NCT04998201 · Mixed Dyslipidemia ARO-APOC3, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 353 | Feb 10, 2023 | Registry ↗ |
| Apr 9, 2026 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease NCT05276570 · Asthma ARO-RAGE, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Completed | 127 | Apr 16, 2025 | Registry ↗ |
| Mar 24, 2026 | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia NCT04720534 · Severe Hypertriglyceridemia ARO-APOC3, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 229 | Mar 9, 2023 | Registry ↗ |
| Mar 3, 2026 | Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in… NCT06796426 · Familial Chylomicronemia, High Risk Severe Hypertriglycerid… Plozasiran | ARWR Arrowhead Pharmaceuticals | — | Available | — | — | Registry ↗ |
| Jan 13, 2026 | Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chron… NCT02738008 · Hepatitis B ARC-520 Injection, entecavir | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 12 | Dec 2016 | Registry ↗ |
| Jan 13, 2026 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic He… NCT02604212 · Hepatitis B ARC-520, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 32 | Dec 2016 | Registry ↗ |
| Jan 13, 2026 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic He… NCT02604199 · Hepatitis B ARC-520 Injection, placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 58 | Jan 2017 | Registry ↗ |
| Jan 13, 2026 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B V… NCT02577029 · Hepatitis B, Hepatitis D ARC-520, entecavir | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 79 | Dec 2016 | Registry ↗ |
| Jan 13, 2026 | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers NCT02535416 · Healthy ARC-520, cetirizine | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 40 | Aug 2016 | Registry ↗ |
| Jan 13, 2026 | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Redu… NCT02065336 · Hepatitis B, Chronic ARC-520, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 58 | Jan 2017 | Registry ↗ |
| Jan 12, 2026 | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) NCT02797522 · Hepatitis B ARC-521 Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Terminated | 47 | Nov 2016 | Registry ↗ |
| Jan 12, 2026 | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (… NCT02363946 · Alpha-1 Antitrypsin Deficiency ARC-AAT Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Terminated | 65 | Nov 2016 | Registry ↗ |
| Dec 26, 2025 | Study of ARC-520 in Patient With Chronic Hepatitis B Virus NCT02349126 · Chronic Hepatitis B ARC-520 Injection | ARWR Arrowhead Pharmaceuticals | Phase 2 | Withdrawn | 0 | Dec 2015 | Registry ↗ |
| Dec 26, 2025 | Safety and Tolerability Study of ARC-520 in Healthy Volunteers NCT01872065 · Healthy ARC-520, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 54 | Sep 2014 | Registry ↗ |
| Dec 24, 2025 | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial… NCT03783377 · Hypertriglyceridemia, Familial Chylomicronemia ARO-APOC3, sterile normal saline (0.9% NaCl) | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 112 | Feb 11, 2021 | Registry ↗ |
| Dec 24, 2025 | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients NCT03747224 · Dyslipidemias, Familial Hypercholesterolemia ARO-ANG3, sterile normal saline (0.9% NaCl) | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 93 | May 17, 2021 | Registry ↗ |
| Dec 24, 2025 | Study of ARO-AAT in Normal Adult Volunteers NCT03362242 · Alpha 1-Antitrypsin Deficiency ARO-AAT Injection, Sterile Normal Saline (0.9% NaCl) | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 45 | Oct 23, 2018 | Registry ↗ |
| Dec 18, 2025 | Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitr… NCT02900183 · Alpha-1 Antitrypsin Deficiency ARC-AAT Injection | ARWR Arrowhead Pharmaceuticals | Phase 2 | Withdrawn | 0 | Nov 2016 | Registry ↗ |
| Dec 17, 2025 | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis NCT04375514 · Cystic Fibrosis, Pulmonary ARO-ENaC, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Terminated | 43 | May 9, 2021 | Registry ↗ |
| Dec 3, 2025 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia NCT04832971 · Mixed Dyslipidemia ARO-ANG3, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 204 | Aug 30, 2022 | Registry ↗ |
| Nov 4, 2025 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) NCT03945292 · Alpha 1-Antitrypsin Deficiency Fazisiran Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 40 | Nov 8, 2021 | Registry ↗ |
| Nov 3, 2025 | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatiti… NCT02452528 · Chronic Hepatitis B ARC-520, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 2 | Terminated | 4 | Dec 2016 | Registry ↗ |
| Oct 22, 2025 | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) NCT03365947 · Hepatitis B ARO-HBV, Sterile Normal Saline (0.9% NaCl) | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Completed | 114 | Apr 23, 2020 | Registry ↗ |
| Oct 15, 2025 | Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated L… NCT03946449 · Alpha 1-Antitrypsin Deficiency ARO-AAT | ARWR Arrowhead Pharmaceuticals | Phase 2 | Completed | 16 | Apr 28, 2022 | Registry ↗ |
| Oct 9, 2025 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT04169711 · Clear Cell Renal Cell Carcinoma ARO-HIF2 | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 26 | Jan 24, 2022 | Registry ↗ |
| Oct 3, 2025 | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Su… NCT04202354 · Non-alcoholic Steatohepatitis ARO-HSD Injection, sterile normal saline (0.9% NaCl) | ARWR Arrowhead Pharmaceuticals | Phase 1/2 | Completed | 50 | Sep 3, 2021 | Registry ↗ |
| Apr 17, 2024 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) NCT05949294 · Amyotrophic Lateral Sclerosis ARO-SOD1 Injection | ARWR Arrowhead Pharmaceuticals | Phase 1 | Withdrawn | 0 | Mar 2025 | Registry ↗ |
| Mar 29, 2024 | Study of ARO-RAGE in Healthy Subjects NCT05533294 · Asthma ARO-RAGE Injection, Placebo | ARWR Arrowhead Pharmaceuticals | Phase 1 | Completed | 43 | Feb 8, 2024 | Registry ↗ |
50 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances